CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Castle Biosciences Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Castle Biosciences Inc
505 S Friendswood Drive, Suite 401
Phone: (281) 796-9032p:281 796-9032 FRIENDSWOOD, TX  77546  United States Ticker: CSTLCSTL
Business Summary
Castle Biosciences, Inc. is a diagnostics company improving health through tests that guide patient care. The Company’s portfolio consists of tests for skin cancers, Barrett’s esophagus, mental health conditions and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-Melanoma is its risk stratification gene expression profile (GEP) test that predicts the likelihood of positive sentinel lymph node and the risk of metastasis, or recurrence, for patients diagnosed with invasive cutaneous melanoma (CM). DecisionDx-SCC is its GEP test for use in patients with cutaneous squamous cell carcinoma (SCC).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
2835 In vitro and in vivo diagnostic substances
8071 Medical laboratories
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Daniel M.Bradbury 63 9/1/2014 9/1/2012
President, Chief Executive Officer, Founder, Director Derek J.Maetzold 62 9/1/2007 9/1/2007
Chief Financial Officer FrankStokes 54 12/1/2017 12/1/2017
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
AltheaDx Inc 3030 Bunker Hill Street San Diego CA United States
Cernostics, Inc. 235 William Pitt Way Pittsburgh PA United States

Business Names
Business Name
AltheaDx Inc
AltheaDx, Inc.
Castle Narnia Way Real Estate Holding 1, LLC
Cernostics, Inc.
CSTL
Myriad myPath, LLC

General Information
Number of Employees: 761 (As of 12/31/2024)
Outstanding Shares: 28,844,937 (As of 4/1/2025)
Shareholders: 90
Stock Exchange: NASD
Federal Tax Id: 770701774
Fax Number: (302) 636-5454


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025